Health
Should AstraZeneca Be Your Next Coronavirus Buy? – The Motley Fool
The drugmaker might well win the coronavirus vaccine race. What would that mean for its stock?
With no end in sight for the coronavirus pandemic, the world is seeing a frantic effort to develop a vaccine for the deadly virus. SARS-CoV-2, the coronavirus responsible for the COVID-19 disease, has taken close to 833,000 lives worldwide. Global recorded cases stand at 24 million, with 5.8 million — and more than 180,000 COVID-related deaths — in the U.S. alone.
AstraZeneca (NYSE:AZN), based in Cambridge, U.K., is working with the University of Oxford to develop its vaccine candidate, AZD12…
-
Noosa News15 hours agoMitch Power Quick Shear event gets men talking about mental health
-
General17 hours agoThailand punches above its weight in film creativity and cross-border appeal. Here’s why
-
General10 hours agoAFL Round 18 live updates: Bulldogs vs Crows, Giants vs Cats, Tigers vs Bombers, Dockers vs Hawks — blog, scores and stats
-
Noosa News18 hours agoRaising your voice | Noosa Today